Description: |
The US Food and Drug Administration (FDA) has approved the first cancer drug to inhibit a protein - called MEK - that acts in a pathway that fuels tumour growth. The drug, called Mekinist (trametinib), was approved for use in advanced melanomas with specific mutations. Other MEK-targeting drugs are being studied in a wide range of tumours, including lung and thyroid cancers. [Source: Nature News Blog]
|
|